QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Global Intellectual Property Portfolio Supporting OT-101 Across Neurology and CNS Delivery
Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Bioscience announced key advancements in their global intellectual property portfolio supporting OT-101, a proprietary TGF-β antisense therapeutic platform, with allowed patent claims in Australia covering OT-101 (SEQ ID NO:9) for the treatment of Parkinson’s Disease, including associated sleep-related symptoms, and granted utility model patents in China and Germany for an intracranial continuous infusion delivery device. The company stated the expanded protection spans therapeutic use claims, CNS delivery methods, device-enabled administration and broader oncology and neurology applications, forming an integrated commercialization platform intended to strengthen long-term defensibility, support strategic partnerships and enhance shareholder value, with additional data presentations planned…